| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
WWL-70 is a novel, potent inhibitor of α/β-hydrolase domain 6 (ABHD6) with IC50 of 70 nM. α/β-hydrolase domain 6 is an enzyme which catalyzes the hydrolysis of 2-arachidonylglycerol.
| ln Vitro |
When compared to untreated cells, 2-arachidonoylglycerol (2-AG) rose by 20% an hour after WWL70 (10 μM) treatment. WWL70 totally prevented the rise in PGE2 brought on by lipopolysaccharide (LPS) at 1 or 10 μM. WWL70 also decreased the mRNA expression of LPS-enhanced mPGES-1 and mPGES-2. About 100 nM is the IC50 of WWL70, which inhibits PGE2 biosynthesis[2].
|
|---|---|
| ln Vivo |
Treatment with 10 mg/kg WWL70 considerably improved performance, while post-treatment with 5 mg/kg WWL70 showed little impact. In traumatic brain injury (TBI) mice, WWL70 therapy enhances motor coordination in a concentration-dependent way. The fall latency rose in rats given 5 mg/kg WWL70 on days 3 and 7, respectively, from 74.92±4.8 to 99.57±5.21 (p<0.01) and 87.32±4.42 to 100.14±3.56 (p<0.05). injuries in comparison to the TBI group of vehicles. Beginning on the first day following injury, motor coordination is improved by WWL70 at a therapeutic level of 10 mg/kg. TBI mice treated with WWL70 were able to consistently switch arms throughout Y-maze exploration (69.67±4.98%) [3].
|
| References |
[1]. Li W, et al. A functional proteomic strategy to discover inhibitors for uncharacterized hydrolases. J Am Chem Soc. 2007 Aug 8;129(31):9594-5.
[2]. Tanaka M, et al. WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation. 2017 Jan 10;14(1):7. [3]. Tchantchou F, et al. Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury. J Neurotrauma. 2013 Apr 1;30(7) |
| Molecular Formula |
C27H23N3O3
|
|---|---|
| Molecular Weight |
437.48982
|
| CAS # |
947669-91-2
|
| SMILES |
CN(C(OC1=CC=C(C2=CC=C(C(N)=O)C=C2)C=C1)=O)CC3=CC=CC(C4=CC=NC=C4)=C3
|
| InChi Key |
QTWNORFUQILKJL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H23N3O3/c1-30(18-19-3-2-4-24(17-19)22-13-15-29-16-14-22)27(32)33-25-11-9-21(10-12-25)20-5-7-23(8-6-20)26(28)31/h2-17H,18H2,1H3,(H2,28,31)
|
| Chemical Name |
4'-carbamoyl-[1,1'-biphenyl]-4-yl methyl(3-(pyridin-4-yl)benzyl)carbamate
|
| Synonyms |
WWL 70 WWL70 WWL-70.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~17.33 mg/mL (~39.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.71 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.2 mg/mL (5.03 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2858 mL | 11.4288 mL | 22.8577 mL | |
| 5 mM | 0.4572 mL | 2.2858 mL | 4.5715 mL | |
| 10 mM | 0.2286 mL | 1.1429 mL | 2.2858 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA